Goodrich Katherine sold $183K of TARS

Goodrich Katherine sold 2,954 shares of Tarsus Pharmaceuticals, Inc. (TARS) at $62.08 ($0.18M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Goodrich Katherine
Published Jun 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
high confidence
Mentioned
$TARS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price, and that it was executed under a pre-arranged Rule 10b5-1 plan; there is no accompanying operational or financial update.

02

Market read

Traders may treat this as routine insider liquidity disclosure with limited directional implications absent other catalysts.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total holdings beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: Filed June 17, covering a June 15 sale.

Background

This is an SEC Form 4 insider transaction for Tarsus Pharmaceuticals, Inc., reported by director Katherine Goodrich.

Company-level read

Ticker impact

$TARSNeutralHigh confidence
Context

Tarsus Pharmaceuticals director Katherine Goodrich sold 2,954 shares at $62.08 via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an insider transaction disclosure, not earnings, guidance, or a business-changing event; 10b5-1 plans typically reduce interpretive value.

Market effects

Minimal, as the disclosure does not indicate sector-wide regulatory, clinical, or commercial changes.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, unusually large or clustered insider selling can sometimes coincide with private information; traders may still monitor for follow-on sales or buys.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Katherine Goodrich

    Director who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.